These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36127336)

  • 1. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.
    Lamers C; Xue X; Smieško M; van Son H; Wagner B; Berger N; Sfyroera G; Gros P; Lambris JD; Ricklin D
    Nat Commun; 2022 Sep; 13(1):5519. PubMed ID: 36127336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
    Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
    Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of compstatin family as therapeutic complement inhibitors.
    Huang Y
    Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
    Hughes S; Gumas J; Lee R; Rumano M; Berger N; Gautam AK; Sfyroera G; Chan AL; Gnanaguru G; Connor KM; Kim BJ; Dunaief JL; Ricklin D; Hajishengallis G; Yancopoulou D; Reis ES; Mastellos DC; Lambris JD
    Clin Immunol; 2020 May; 214():108391. PubMed ID: 32229292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
    Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
    J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.
    Magotti P; Ricklin D; Qu H; Wu YQ; Kaznessis YN; Lambris JD
    J Mol Recognit; 2009; 22(6):495-505. PubMed ID: 19658192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.
    Huang Y; Reis ES; Knerr PJ; van der Donk WA; Ricklin D; Lambris JD
    ChemMedChem; 2014 Oct; 9(10):2223-6. PubMed ID: 25056114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
    Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
    Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
    Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
    Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 12. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.
    Sahu A; Morikis D; Lambris JD
    Mol Immunol; 2003 Jan; 39(10):557-66. PubMed ID: 12431389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile after prolonged C3 inhibition.
    Reis ES; Berger N; Wang X; Koutsogiannaki S; Doot RK; Gumas JT; Foukas PG; Resuello RRG; Tuplano JV; Kukis D; Tarantal AF; Young AJ; Kajikawa T; Soulika AM; Mastellos DC; Yancopoulou D; Biglarnia AR; Huber-Lang M; Hajishengallis G; Nilsson B; Lambris JD
    Clin Immunol; 2018 Dec; 197():96-106. PubMed ID: 30217791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors.
    Mastellos DC; Ricklin D; Sfyroera G; Sahu A
    Clin Immunol; 2022 Feb; 235():108785. PubMed ID: 34147650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. With complements: C3 inhibition in the clinic.
    Kolev M; Barbour T; Baver S; Francois C; Deschatelets P
    Immunol Rev; 2023 Jan; 313(1):358-375. PubMed ID: 36161656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational analysis of complement inhibitor compstatin using molecular dynamics.
    Devaurs D; Antunes DA; Kavraki LE
    J Mol Model; 2020 Aug; 26(9):231. PubMed ID: 32789582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
    Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD
    J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
    Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
    Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.
    Primikyri A; Papanastasiou M; Sarigiannis Y; Koutsogiannaki S; Reis ES; Tuplano JV; Resuello RR; Nilsson B; Ricklin D; Lambris JD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1041-1042():19-26. PubMed ID: 27992787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.